Evidence map›Paper›PMID 33321866›Full record

ReviewCells2020

Ca

John McDaid, Sarah Mustaly-Kalimi, Grace E Stutzmann

Open access · goldAbstract readReview
In one paragraph

Review in Cells, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 45 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
45citing papers in PubMed, 1 pooled it
4.0field-weighted citation impact, top 6% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

45 citing papers in PubMed, 1 synthesis or guideline pooled it, 67 citations in OpenAlex.

  1. Pooled it
  2. Article
  3. Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Review
  9. A Review on the Pathophysiology of Alzheimer's Disease.Current protein & peptide science · 2026
    Review
  10. Review
  11. Review
  12. Article
  13. Article
  14. Article
  15. Review
  16. Review
  17. Review
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

John McDaidCenter for Neurodegenerative Disease and Therapeutics, Rosalind Franklin University of Medicine and Science, 3333 Green Bay Rd., North Chicago, IL 60064, USA.ORCID 0000-0002-1939-720X
Sarah Mustaly-KalimiCenter for Neurodegenerative Disease and Therapeutics, Rosalind Franklin University of Medicine and Science, 3333 Green Bay Rd., North Chicago, IL 60064, USA.
Grace E StutzmannCenter for Neurodegenerative Disease and Therapeutics, Rosalind Franklin University of Medicine and Science, 3333 Green Bay Rd., North Chicago, IL 60064, USA.ORCID 0000-0003-2841-8532
Rosalind Franklin University of Medicine and Science · US

Funding

Novel Drug Discovery for AD Targeting Ryanodine Calcium ChannelsRF1AG047237 · NIA · ROSALIND FRANKLIN UNIV OF MEDICINE & SCI · PI BUOLAMWINI, JOHN K, STUTZMANN, GRACE E. · 2016 to 2016
$1.9M
Intracellular organelle deficits driving Alzheimer's diseaseRF1AG065628 · NIA · ROSALIND FRANKLIN UNIV OF MEDICINE & SCI · PI SEKLER, ISRAEL, STUTZMANN, GRACE E. · 2020 to 2020
$1.7M
Cellular and synaptic signaling mechanisms driving early AD pathologyR56AG055497 · NIA · ROSALIND FRANKLIN UNIV OF MEDICINE & SCI · PI STUTZMANN, GRACE E. · 2018 to 2018
$390k
NIA NIH HHS R56 AG055497NIA NIH HHS RF1 AG047237NIA NIH HHS RF1 AG065628
6 · The paper itself

Abstract

Ca

Indexed as

Calcium SignalingAlzheimer DiseaseCytosolEndoplasmic ReticulumHumansNeuronsOxidative StressRyanodine Receptor Calcium Release ChannelSynapsesRyanodine Receptor Calcium Release Channelautophagycalciumglutamatelysosomemitochondrianicotinic receptorssynaptic

Identifiers

PMID33321866
PMCPMC7763805
OpenAlexW3112777679

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.